Ian Mortimer, President and CEO of Xenon Pharmaceuticals Inc. ($XENE), sold about $20.9 million in company shares on the open market seventeen times over the last year. His most recent sale occurred on March 10, 2026. These XENE insider sales rank 654th out of 11,678 individuals, surpassing the average of $8.6 million per seller and 6.4 transactions. Mortimer made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 12500 | $0.00 | 41,531.0000 | 79,247,976 | 43.06% | 0.02% |
| March 12, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Restricted Share Units | 12500 | $0.00 | 37,500.0000 | 79,247,976 | 25.00% | 0.02% |
| March 13, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 7308 | $55.23 | 34,223.0000 | 79,247,976 | 17.60% | 0.01% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option | 65000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.08% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option | 105000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.13% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option | 25000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option | 75000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.09% |
| March 10, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 11269 | $60.11 | 29,031.0000 | 79,247,976 | 27.96% | 0.01% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 20000 | $0.00 | 40,300.0000 | 79,247,976 | 98.52% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 65000 | $62.06 | 20,300.0000 | 79,247,976 | 76.20% | 0.08% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 65000 | $9.44 | 85,300.0000 | 79,247,976 | 320.20% | 0.08% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 61652 | $60.08 | 20,300.0000 | 79,247,976 | 75.23% | 0.08% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 43348 | $59.26 | 86,952.0000 | 79,247,976 | 33.27% | 0.05% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 105000 | $4.75 | 125,300.0000 | 79,247,976 | 517.24% | 0.13% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 2449 | $61.26 | 20,300.0000 | 79,247,976 | 10.77% | 0.00% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 10072 | $60.47 | 22,749.0000 | 79,247,976 | 30.69% | 0.01% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 12479 | $59.50 | 32,821.0000 | 79,247,976 | 27.55% | 0.02% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 25000 | $3.10 | 45,300.0000 | 79,247,976 | 123.15% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 21515 | $60.49 | 20,300.0000 | 79,247,976 | 51.45% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 31694 | $59.88 | 41,815.0000 | 79,247,976 | 43.12% | 0.04% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 75000 | $8.40 | 95,300.0000 | 79,247,976 | 369.46% | 0.09% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 21791 | $58.81 | 73,509.0000 | 79,247,976 | 22.87% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Performance Share Units | 20000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.03% |
| March 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Performance Share Units | 20000 | $0.00 | 20,000.0000 | 79,247,976 | 9999.99% | 0.03% |
| Jan. 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Share Option (Right to Buy) | 350000 | $0.00 | 350,000.0000 | 79,247,976 | 9999.99% | 0.44% |
| Jan. 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Restricted Share Units | 65000 | $0.00 | 65,000.0000 | 79,247,976 | 9999.99% | 0.08% |
| Jan. 2, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 40000 | $7.49 | 60,300.0000 | 79,247,976 | 197.04% | 0.05% |
| Jan. 2, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option (Right to Buy) | 40000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.05% |
| Jan. 2, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 2062 | $44.93 | 20,300.0000 | 79,247,976 | 9.22% | 0.00% |
| Jan. 2, 2026 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 37938 | $44.40 | 22,362.0000 | 79,247,976 | 62.92% | 0.05% |
| Dec. 5, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 14375 | $45.03 | 31,130.0000 | 79,247,976 | 31.59% | 0.02% |
| Dec. 8, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 2010 | $46.32 | 20,300.0000 | 79,247,976 | 9.01% | 0.00% |
| Dec. 8, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 8820 | $45.59 | 22,310.0000 | 79,247,976 | 28.33% | 0.01% |
| Nov. 28, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 97 | $45.01 | 45,505.0000 | 79,247,976 | 0.21% | 0.00% |
| Oct. 1, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | S | Common Shares | 25000 | $40.16 | 45,602.0000 | 79,247,976 | 35.41% | 0.03% |
| Oct. 1, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 0.0000 | 79,247,976 | 100.00% | 0.03% |
| Oct. 1, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | M | Common Shares | 25000 | $7.69 | 70,602.0000 | 79,247,976 | 54.82% | 0.03% |
| March 12, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Restricted Share Units | 50000 | $0.00 | 50,000.0000 | 77,894,643 | 9999.99% | 0.06% |
| March 12, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Share Option (Right to Buy) | 275000 | $0.00 | 275,000.0000 | 77,894,643 | 9999.99% | 0.35% |
| Jan. 27, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option (Right to Buy) | 16315 | $0.00 | 0.0000 | 77,894,643 | 100.00% | 0.02% |
| Jan. 24, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option (Right to Buy) | 22468 | $0.00 | 16,315.0000 | 77,894,643 | 57.93% | 0.03% |
| Jan. 23, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Stock Option (Right to Buy) | 16217 | $0.00 | 38,783.0000 | 77,894,643 | 29.49% | 0.02% |
| Jan. 27, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 1149 | $41.07 | 45,602.0000 | 77,894,643 | 2.46% | 0.00% |
| Jan. 27, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 1149 | $17.76 | 46,751.0000 | 77,894,643 | 2.52% | 0.00% |
| Jan. 27, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 15166 | $40.46 | 45,602.0000 | 77,894,643 | 24.96% | 0.02% |
| Jan. 27, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 15166 | $17.76 | 60,768.0000 | 77,894,643 | 33.26% | 0.02% |
| Jan. 24, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 22468 | $40.20 | 45,602.0000 | 77,894,643 | 33.01% | 0.03% |
| Jan. 24, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 22468 | $17.76 | 68,070.0000 | 77,894,643 | 49.27% | 0.03% |
| Jan. 23, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | S | Common Shares | 16217 | $40.08 | 45,602.0000 | 77,894,643 | 26.23% | 0.02% |
| Jan. 23, 2025 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | M | Common Shares | 16217 | $17.76 | 61,819.0000 | 77,894,643 | 35.56% | 0.02% |
| March 11, 2024 | Xenon Pharmaceuticals Inc. | $XENE | MORTIMER IAN | PRESIDENT & CEO | A | Stock Option (Right to Buy) | 250000 | $0.00 | 250,000.0000 | 66,889,005 | 9999.99% | 0.37% |